Genfit Investor Relations Material

Genfit S.A. is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions in the areas of liver-related diseases and metabolic disorders. The company specializes in creating proprietary drug candidates and biomarkers to address unmet medical needs, particularly in non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. Genfit's portfolio includes both therapeutic and diagnostic assets aimed at improving patient outcomes through targeted treatment strategies and precision medicine. The company is headquartered in Loos, France, and its shares are listed on the Euronext Paris.